Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DE stock price vs ABT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ABT's multiple
Needs ABT P/E.
Implied fair value · at DE's multiple
Needs DE P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DEERE & CO · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CATERPILLAR INC
DE vs CAT
AGCO CORP /DE
DE vs AGCO
TORO CO
DE vs TTC
TITAN INTERNATIONAL INC
DE vs TWI
Johnson & Johnson
DE vs JNJ
Medtronic plc
DE vs MDT
BECTON DICKINSON & CO
DE vs BDX
Thermo Fisher Scientific Inc.
DE vs TMO
DANAHER CORP /DE/
DE vs DHR
BOSTON SCIENTIFIC CORP
DE vs BSX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DE can re-accelerate revenue growth and sustain its current margin structure, then holding or buying on weakness is reasonable because the stock already trades near ABT-based valuation but above DCF value; if growth remains negative, the current P/E premium looks difficult to justify.
DE trades at $592.67 versus an ABT-based implied price of $525.66, implying 11.3% downside. On a relative basis, DE looks more expensive on P/E but roughly in line on EV/EBITDA and EV/Revenue, suggesting the premium is coming more from earnings multiple than enterprise value metrics.
Supporting Metrics
